Dana-Farber experts recommend actionable steps to enhance the rigor and transparency of FDA validation standards for radiology AI software.
Key Details
- 1The current FDA regulatory framework for SaMD validation is flexible but lacks explicit, consistent standards for radiology AI.
- 2Common radiology SaMD types include CADq, CADt, CADe, CADx, CADe/x, and CADa/o.
- 3Retrospective validation is typical for assistive radiology AI; prospective studies are standard for autonomous devices.
- 4Concerns exist over inadequate evaluation metrics for generative models and the use of synthetic data for some devices.
- 5Recommendations include removing nonclinical validation for certain devices, requiring more reader and prospective studies, adopting mandatory reporting checklists, and creating a public validation database.
Why It Matters
Clear and consistent FDA standards are crucial for ensuring the clinical reliability, performance, and reporting transparency of AI tools used in radiology, directly impacting adoption and trust among professionals and patients.
Source
AuntMinnie
Related News
•AuntMinnie
Vast Majority of FDA-Cleared Radiology AI Devices Lack Outcome Trials
Only 0.3% of FDA-cleared radiology AI devices have registered trials on patient outcomes, raising concerns about evidence standards.
•Radiology Business
Radiology Partners Urges FDA for Clarity on Imaging AI Regulations
Radiology Partners and Mosaic Clinical Technologies petition the FDA for clearer regulatory guidelines on imaging AI vision-language models.
•Radiology Business
FDA Solicits Public Input on Regulating Generative AI in Medical Devices
The FDA is seeking public feedback on how to regulate generative AI in medical devices, recognizing both its promise and risks.